• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

Stiefel Laboratories to acquire Barrier Therapeutics

Coral Gables, Fla. - Stiefel Laboratories has announced it has signed a definitive merger agreement to acquire Barrier Therapeutics, according to PRNewswire.

Coral Gables, Fla.

- Stiefel Laboratories has announced it has signed a definitive merger agreement to acquire Barrier Therapeutics, according to PRNewswire.

The transaction is valued at approximately $148 million, and is subject to valid tender of a majority of Barrier Therapeutics' fully diluted common stock, regulatory approvals and other customary conditions.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
2 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
4 experts are featured in this series.
2 experts in this video
1 expert in this video
4 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.